Kymera Therapeutics advances Phase 2 trials of KT-474 in partnership with Sanofi
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a leader in the biopharmaceutical sector focusing on targeted protein degradation (TPD), has announced a significant expansion of its ongoing Phase 2 clinical trials for KT-474. This decision, influenced by positive preliminary safety and efficacy data reviewed by an Independent Data Review Committee, was communicated by Sanofi, Kymera’s strategic partner. […]